Search

HOSPITAL FRAILTY RISK SCORE IS AN INDEPENDENT PREDICTOR OF OUTCOMES IN CUTANEOUS SQUAMOUS CELL CARCINOMAS OF HEAD AND NECK REGION.

Skin Cancer

Rema A Kandula, MD; Sandeep Kandregula, MD; Bharat Guthikonda, MD; John Pang, MD; Ameya Asarkar, MD; Cherie-Ann O Nathan, MD

LSU Health sciences Shreveport

THE ARGUMENT FOR ADJUVANT THERAPY FOR STAGE II HEAD AND NECK MELANOMA- COULD A NOMOGRAM ASSIST DECISION MAKING?

Skin Cancer

Helena Levyn, MD; Schlomo Schneebaum, MD

Tel Aviv Sourasky Medical Center

CUTANEOUS SQUAMOUS CELL CARCINOMA IN IMMUNOCOMPROMISED PATIENTS- A COMPARISON BETWEEN DIFFERENT IMMUNOMODULATING CONDITIONS

Skin Cancer

Ofir Zavdy, MD, MPH; Tara Coreanu, MD; Dvir Bar On, MD; Amit Ritter, MD; Gideon Bachar, MD; Thomas Shpitzer, MD; Noga Kurman, MD; Muhammad Mansour, MD; Dean Ad-El, MD; Uri Rozovski, MD; Gilad Itzhaki, MD; Shani Sherman-Bergman, MD; Limor Azulay-Gitter, MD; Aviram Mizrachi, MD

Rabin Medical Center

A VACCINE FOR SKIN CANCER?: PREVIOUS HPV-POSITIVE CANCER AND HPV VACCINATION ASSOCIATION WITH CUTANEOUS SQUAMOUS CELL CARCINOMA

Skin Cancer

Susan Kurian, MD; Gauri Shishodia, PhD; Ashley Flowers, MD; Brent Chang, MD, FACS; Cherie-Ann O Nathan, MD, FACS

Ochsner LSU Health Shreveport